TheStreet upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN) from a d+ rating to a c- rating in a research report sent to investors on Friday.

Several other research analysts also recently weighed in on the stock. JPMorgan Chase & Co. upped their price objective on shares of BioMarin Pharmaceutical from $127.00 to $133.00 and gave the stock an overweight rating in a report on Thursday, May 31st. Zacks Investment Research downgraded shares of BioMarin Pharmaceutical from a buy rating to a hold rating in a report on Wednesday, April 25th. Credit Suisse Group upped their price objective on shares of BioMarin Pharmaceutical from $120.00 to $122.00 and gave the stock an outperform rating in a report on Monday, July 9th. Citigroup upped their price objective on shares of BioMarin Pharmaceutical to $108.00 and gave the stock a buy rating in a report on Tuesday, May 29th. Finally, BidaskClub downgraded shares of BioMarin Pharmaceutical from a sell rating to a strong sell rating in a report on Tuesday, April 24th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. BioMarin Pharmaceutical presently has a consensus rating of Buy and a consensus target price of $116.28.

BMRN opened at $99.03 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.24 and a current ratio of 2.83. BioMarin Pharmaceutical has a 1-year low of $75.81 and a 1-year high of $106.20. The firm has a market cap of $17.94 billion, a price-to-earnings ratio of -147.81 and a beta of 1.60.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). BioMarin Pharmaceutical had a negative return on equity of 3.00% and a negative net margin of 8.68%. The business had revenue of $372.80 million for the quarter, compared to analyst estimates of $359.25 million. During the same quarter in the previous year, the company posted ($0.21) EPS. The business’s quarterly revenue was up 17.4% on a year-over-year basis. equities research analysts anticipate that BioMarin Pharmaceutical will post -0.24 earnings per share for the current year.

In other news, EVP Robert Baffi sold 5,173 shares of the company’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $105.00, for a total value of $543,165.00. Following the completion of the sale, the executive vice president now owns 83,276 shares in the company, valued at approximately $8,743,980. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Brian Mueller sold 2,021 shares of the company’s stock in a transaction on Friday, June 15th. The stock was sold at an average price of $94.50, for a total transaction of $190,984.50. Following the completion of the sale, the senior vice president now owns 13,029 shares of the company’s stock, valued at approximately $1,231,240.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 65,874 shares of company stock valued at $6,259,566. Company insiders own 1.90% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Waddell & Reed Financial Inc. grew its position in BioMarin Pharmaceutical by 5.0% during the second quarter. Waddell & Reed Financial Inc. now owns 3,337,346 shares of the biotechnology company’s stock valued at $314,378,000 after buying an additional 160,247 shares during the period. Palo Alto Investors LP grew its position in BioMarin Pharmaceutical by 1.9% during the first quarter. Palo Alto Investors LP now owns 2,545,482 shares of the biotechnology company’s stock valued at $206,362,000 after buying an additional 47,676 shares during the period. USS Investment Management Ltd grew its position in BioMarin Pharmaceutical by 22.9% during the first quarter. USS Investment Management Ltd now owns 1,339,671 shares of the biotechnology company’s stock valued at $111,869,000 after buying an additional 249,738 shares during the period. Thrivent Financial for Lutherans grew its position in BioMarin Pharmaceutical by 581.0% during the first quarter. Thrivent Financial for Lutherans now owns 1,224,776 shares of the biotechnology company’s stock valued at $99,293,000 after buying an additional 1,044,921 shares during the period. Finally, Frontier Capital Management Co. LLC grew its position in BioMarin Pharmaceutical by 42.8% during the second quarter. Frontier Capital Management Co. LLC now owns 1,210,472 shares of the biotechnology company’s stock valued at $114,026,000 after buying an additional 362,531 shares during the period.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Recommended Story: Relative Strength Index

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.